• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.03% Nasdaq Up0.17%

    More On OXB.L

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Oxford BioMedica PLC (OXB.L)

    -LSE
    5.30 0.00(0.00%) Dec 24, 5:22AM EST
    Add to Portfolio
    ProfileGet Profile for:
    Oxford BioMedica PLC
    Medawar Centre
    Robert Robinson Avenue
    Oxford, OX4 4GA
    United Kingdom - Map
    Phone: 44 18 6578 3000
    Fax: 44 18 6578 3001
    Website: http://www.oxfordbiomedica.co.uk

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:106

    Business Summary 

    Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ‘wet’ age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Oxford BioMedica PLC

    Key Executives 
     PayExercised
    Mr. John Dawson , 54
    Chief Exec. Officer and Director
    N/AN/A
    Mr. Timothy William Watts , 56
    Chief Financial Officer, Company Sec. and Director
    280.00KN/A
    Dr. Paul Blake M.D., 66
    Chief Devel. Officer, Director, Chairman of Remuneration Committee and Member of Nomination Committee
    38.00KN/A
    Mr. Peter Nolan , 61
    Chief Bus. Officer and Exec. Director
    N/AN/A
    Lara Mott ,
    Head of Corp. Communications
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in GBp.